Ascletis' Strategic Partner Sagimet Announces First Patient Dosed in Phase III U.S. Clinical Trial of Denifanstat (ASC40) for Moderate to Severe Acne
- With first patient dosed in Phase III clinical trial, Ascletis' strategic partner Sagimet Biosciences Inc. ("Sagimet") advances denifanstat (ASC40)'s U.S. registrational program, building on positive Phase III clinical results in China from...
Ascletis Announces Positive Topline Results from Its Phase III Open-Label Study of Denifanstat (ASC40), a First-in-Class, Once-Daily Oral FASN Inhibitor for Acne
- Denifanstat (ASC40), a once-daily oral fatty acid synthase (FASN) inhibitor, demonstrated favorable safety and tolerability in a Phase III open-label study - The exceptional efficacy of denifanstat (ASC40) observed in the Company's previously...
Ascletis Announces China National Medical Products Administration Acceptance of New Drug Application for Denifanstat (ASC40), a First-in-Class FASN Inhibitor for Acne Treatment
-Denifanstat (ASC40) met all primary, key secondary and secondary efficacy endpoints (ITT analysis) and significantly improved moderate-to-severe acne vulgaris compared with placebo in a randomized, double-blind, placebo-controlled, multicenter...